Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer
The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Standard chemotherapy is associated with low response rates and short progression-free survival among patients with pretreated metastatic triple-negative breast cancer. Sacituzumab govitecan-hziy is an antibody-drug conjugate that combines a humanized monoclonal antibody, which targets the human trophoblast cell-surface antigen 2 (Trop-2), with SN-38, which is conjugated to the antibody by a cleavable linker. Sacituzumab govitecan-hziy enables delivery of high concentrations of SN-38 to tumors. METHODS: We conducted a phase 1/2 single-group, multicenter trial involving patients with advanced epithelial cancers who received sacituzumab govitecan-hziy intravenously on days 1 and 8 of each 21-day cycle until disease progression or unacceptable toxic effects. A total of 108 patients received sacituzumab govitecan-hziy at a dose of 10 mg per kilogram of body weight after receiving at least two previous anticancer therapies for metastatic triple-negative breast cancer. The end points included safety; the objective response rate (according to Response Evaluation Criteria in Solid Tumors, version 1.1), which was assessed locally; the duration of response; the clinical benefit rate (defined as a complete or partial response or stable disease for at least 6 months); progression-free survival; and overall survival. Post hoc analyses determined the response rate and duration, which were assessed by blinded independent central review. RESULTS: The 108 patients with triple-negative breast cancer had received a median of 3 previous therapies (range, 2 to 10). Four deaths occurred during treatment; 3 patients (2.8%) discontinued treatment because of adverse events. Grade 3 or 4 adverse events (in ≥10% of the patients) included anemia and neutropenia; 10 patients (9.3%) had febrile neutropenia. The response rate (3 complete and 33 partial responses) was 33.3% (95% confidence interval [CI], 24.6 to 43.1), and the median duration of response was 7.7 months (95% CI, 4.9 to 10.8); as assessed by independent central review, these values were 34.3% and 9.1 months, respectively. The clinical benefit rate was 45.4%. Median progression-free survival was 5.5 months (95% CI, 4.1 to 6.3), and overall survival was 13.0 months (95% CI, 11.2 to 13.7). CONCLUSIONS: Sacituzumab govitecan-hziy was associated with durable objective responses in patients with heavily pretreated metastatic triple-negative breast cancer. Myelotoxic effects were the main adverse reactions. (Funded by Immunomedics; IMMU-132-01 ClinicalTrials.gov number, NCT01631552.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The overall response rate was 33.3% (95% CI 24.6-43.1), with a median duration of response of 7.7 months (95% CI 4.9-10.8).”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [72]
In the citing paper
“Of the patients with a response to sacituzumab govitecan-hziy, 55.6% maintained their response for ≥6 months and 16.7% maintained their response for ≥12 months.”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [72]
Citations
Cites
Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer
Schmid, P., Adams, S., Rugo, H. S., Schneeweiss, A., Barrios, C. H., Iwata, H., Diéras, V., Hegg, R., Im, S.-A., Shaw Wright, G., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809615 · Cited by 4,350
Self-citationTrastuzumab emtansine for HER2-positive advanced breast cancer
Verma, S., Miles, D., Gianni, L., Krop, I. E., Welslau, M., Baselga, J., Pegram, M., Oh, D.-Y., Diéras, V., Guardino, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1209124 · Cited by 3,834
Palbociclib and letrozole in advanced breast cancer
Finn, R. S., Martin, M., Rugo, H. S., Jones, S., Im, S.-A., Gelmon, K., Harbeck, N., Lipatov, O. N., Walshe, J. M., Moulder, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607303 · Cited by 3,007
Self-citationCombined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
Flaherty, K. T., Infante, J. R., Daud, A., Gonzalez, R., Kefford, R. F., Sosman, J., Hamid, O., Schuchter, L., Cebon, J., Ibrahim, N., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1210093 · Cited by 2,810
Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer
Shaw, A. T., Ou, S.-H. I., Bang, Y.-J., Camidge, D. R., Solomon, B. J., Salgia, R., Riely, G. J., Varella-Garcia, M., Shapiro, G. I., Costa, D. B., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406766 · Cited by 1,964
Breast cancer statistics, 2015: Convergence of incidence rates between black and white women
DeSantis, C. E., Fedewa, S. A., Goding Sauer, A., Kramer, J. L., Smith, R. A., & Jemal, A. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21320 · Cited by 1,252
Cortes, J., O'Shaughnessy, J., Loesch, D., Blum, J. L., Vahdat, L. T., Petrakova, K., Chollet, P., Manikas, A., Diéras, V., Delozier, T., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60070-6 · Cited by 1,094
Self-citationKohler, B. A., Sherman, R. L., Howlader, N., Jemal, A., Ryerson, A. B., Henry, K. A., Boscoe, F. P., Cronin, K. A., Lake, A., Noone, A.-M., et al. (2015) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djv048 · Cited by 915
Kawato, Y., Aonuma, M., Hirota, Y., Kuga, H., & Sato, K. (1991) · PubMed · Cited by 865
Goldenberg, D. M., Cardillo, T. M., Govindan, S. V., Rossi, E. A., & Sharkey, R. M. (2015) · Oncotarget · doi:10.18632/oncotarget.4318 · Cited by 495
Self-citation
Research works printed but not linked: 1
- 10.1002/(SICI)1097-0215(19980529)76:5<671::AID-IJC10>3.0.CO;2-7 · DOI · Paper page
Cited by
Items 401–500 of 874
Chowdari, N. S., Zhang, Y., McDonald, I. M., Johnson, W. L., Langley, D. R., Sivaprakasam, P., Mate, R. A., Huynh, T., Kotapati, S., Deshpande, M., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01385 · Cited by 18
Improving Antibody‐Tubulysin Conjugates through Linker Chemistry and Site‐Specific Conjugation
Hamilton, J. Z., Pires, T. A., Mitchell, J. A., Cochran, J. H., Emmerton, K. K., Zaval, M. C., Stone, I. J., Anderson, M. E., Jin, S., Waight, A. B., et al. (2020) · ChemMedChem · doi:10.1002/cmdc.202000889 · Cited by 17
Sami, A., & Raza, A. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1457491 · Cited by 19
Yajima, S., & Masuda, H. (2025) · Cancers · doi:10.3390/cancers17091594 · Cited by 18
“The toxicity profile of SG primarily reflects its payload, SN-38, and includes hematologic abnormalities (neutropenia, anemia, and leukopenia) and gastrointestinal symptoms (diarrhea, nausea, and vomiting) [49].”
UGT1A1 and Sacituzumab Govitecan Toxicity: A Systematic Review and Meta‐Analysis
Russo, C. D., Asiimwe, I. G., Pushpakom, S. P., Palmieri, C., & Pirmohamed, M. (2025) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.70060 · Cited by 17
“19,21,22,24 This indicates that systemic exposure to SN-38 is at a high enough level to cause systemic toxicity.”
ASCO 2020: highlights in breast cancer
Bartsch, R. (2021) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-021-00674-9 · Cited by 17
TROP2 as Patient-Tailoring but Not Prognostic Biomarker for Breast Cancer
Liu, X., Zhou, T., Wang, Y., Pei, M., Wang, G., Chu, W., Wang, Q., Du, S., Wang, H., & Wang, C. (2022) · OncoTargets and Therapy · doi:10.2147/ott.s354048 · Cited by 17
“This study aims to investigate the biomarker value of TROP2 for patient-tailoring and prognostic for BC patients, including TNBC. Methods: The levels of TROP2 expression in 404 Chinese BC tissues on tissue microarrays (TMAs) were quantified by immunohistochemistry and their correlations to the clinicopathological fact…”
BackgroundInfluentialPalange, A. L., Mascolo, D. D., Ferreira, M. F. M. M., Gawne, P. J., Spanò, R., Felici, A., Bono, L., Moore, T. L., Salerno, M., Armirotti, A., et al. (2023) · Advanced Science · doi:10.1002/advs.202205223 · Cited by 18
Bao, G., Zhou, H., Zou, S., Chen, L., Zhang, B., Wang, Z., Moon, E. S., Zhao, J., Roesch, F., & Zhu, X. (2023) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.2c01051 · Cited by 19
Basal epithelial cells in prostate development, tumorigenesis, and cancer progression
Pitzen, S. P., & Dehm, S. M. (2023) · Cell Cycle · doi:10.1080/15384101.2023.2206502 · Cited by 21
“Sacituzumab Govitecan has been approved for use in triple-negative breast cancer and advanced bladder cancer, with clinical trials currently underway in CRPC (NCT03725761) [87].”
BackgroundZhang, X., Gao, S., Li, N., Chen, J., Ji, C., Li, X., Jiang, L., Lee, T. K., Keng, V. W., & Zhao, Y. (2023) · Cell Death Discovery · doi:10.1038/s41420-023-01600-0 · Cited by 16
Exploring the therapeutic potential of ADC combination for triple-negative breast cancer
Lu, L., Niu, Z., Chao, Z., Fu, C., Chen, K., & Shi, Y. E. (2023) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-023-04946-x · Cited by 19
“Based on these positive results, the FDA granted accelerated approval of sacituzumab govitecan for the treatment of heavily pre-treated mTNBC patients.”
InfluentialWang, J., Tong, Z., Tan, Y., Shi, Y., Wu, Y., Zhou, Q., Xing, X., Chen, X., Qiu, F., & Ma, F. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101707 · Cited by 16
Mezi, S., Botticelli, A., Pomati, G., Cerbelli, B., Scagnoli, S., Amirhassankhani, S., d’Amati, G., & Marchetti, P. (2021) · Cancers · doi:10.3390/cancers13051080 · Cited by 18
“Such is the case with Poli ADP-ribose polymerase (PARP) inhibitors in BRCA-mutated breast cancer [12,13], serine/threonine protein kinase (AKT) inhibitors in phosphatidylinositol-3-OH kinase (PI3K)/AKT/Phosphatase and tensin homologue (PTEN)-altered TNBC [14,15], and trophoblast cell surface antigen-2 (Trop-2) directe…”
BackgroundMoving Towards Targeted Therapies for Triple-Negative Breast Cancer
Kagihara, J. A., Shagisultanova, E. I., Afghahi, A., & Diamond, J. R. (2021) · Current Breast Cancer Reports · doi:10.1007/s12609-021-00416-0 · Cited by 16
Self-citationAdvances in the management of breast cancer brain metastases
Sammons, S. L., Swearingen, A. E. D. V., Chung, C. D., & Anders, C. K. (2021) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdab119 · Cited by 16
Antibody-Peptide Epitope Conjugates for Personalized Cancer Therapy
Zhang, S., Yan, C., Millar, D. G., Yang, Q., Heather, J., Langenbucher, A., Morton, L. T., Sepulveda, S., Alpert, E. J., Whelton, L. R., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-2200 · Cited by 16
Draoui, Y., Radi, S., Bahjou, Y., Idir, A., Mahdaoui, A. E., Zyad, A., Miras, H. N., Ferbinţeanu, M., Rotaru, A., & Garcia, Y. (2023) · RSC Advances · doi:10.1039/d3ra07714d · Cited by 16
“10 Current TNBC treatment techniques are still inadequate, and poly-chemotherapy is the usual treatment for early TNBC in order to assess tumor sensitivity.”
BackgroundAdvances in the study of marketed antibody-drug Conjugates (ADCs) for the treatment of breast cancer
Liang, Y., Zhang, P., Li, F., Lai, H., Qi, T., & Wang, Y. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1332539 · Cited by 22
Cardillo, T. M., Zalath, M. B., Arrojo, R., Sharkey, R. M., Govindan, S. V., Chang, C., & Goldenberg, D. M. (2024) · Oncotarget · doi:10.18632/oncotarget.28559 · Cited by 18
Self-citationTherapeutic Targets in Advanced Penile Cancer: From Bench to Bedside
Pagliaro, L. C., Tekin, B., Gupta, S., & Hernandez, L. H. (2024) · Cancers · doi:10.3390/cancers16112086 · Cited by 17
“Examples of successful ADCs include those targeting nectin-4 in urothelial carcinoma and targeting trophoblast cell-surface antigen 2 (TROP-2) in breast cancer and urothelial carcinoma [41–43].”
BackgroundLi, C. L., Yuan, X. Y., & Yi, P. (2024) · Cell Biochemistry and Function · doi:10.1002/cbf.70011 · Cited by 17
“…(topoisomerase 1 inhibitor SN ‐ 38 ‐ cleavable linker ‐ humanized anti ‐ Trop ‐ 2 mAb targets Trop ‐ 2 in adult patients with metastatic TNBC) [109], trastuzumab deruxtecan (topoisomerase I inhibitor, an exatecan derivative ‐ tetrapeptide ‐ based linker ‐ trastuzumab target HER2 in metastatic…”
Drug Conjugates for Targeting Eph Receptors in Glioblastoma
Sharma, P., Roberts, C. M., Herpai, D., Fokt, I., Priebe, W., & Debinski, W. (2020) · Pharmaceuticals · doi:10.3390/ph13040077 · Cited by 16
Catalano, M., Bassi, G., Rotondi, G., Khettabi, L., Dichiara, M. G., Murer, P., Scheuermann, J., Soler‐López, M., & Neri, D. (2020) · RSC Medicinal Chemistry · doi:10.1039/d0md00310g · Cited by 15
Targeted Treatment of Triple-Negative Breast Cancer
Young, J. A., & Tan, A. R. (2021) · The Cancer Journal · doi:10.1097/ppo.0000000000000495 · Cited by 15
“Sacituzumab govitecan-hziy was administered at 10 mg/kg IVon days 1 and 8 every 21 days.(87,90) The ORR was 33% (95% CI, 24.”
MethodA year in pharmacology: new drugs approved by the US Food and Drug Administration in 2020
Kayki‐Mutlu, G., & Michel, M. C. (2021) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-021-02085-3 · Cited by 16
“Anemia and neutropenia were the most common AE reported (Bardia et al. 2019).”
BackgroundInfluentialAptamer-drug conjugates: New probes for imaging and targeted therapy
Liu, P., Ga, L., Aodeng, G., Wang, Y., & Ai, J. (2022) · Biosensors and Bioelectronics X · doi:10.1016/j.biosx.2022.100126 · Cited by 21
Current and emerging role of sacituzumab govitecan in the management of urothelial carcinoma
Thomas, V. M., Tripathi, N., Agarwal, N., & Swami, U. (2022) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2022.2049763 · Cited by 15
“by the release of SN-38 extracellularly [20].”
Chen, D.-L., Ma, G., Yang, E.-L., Yang, Y., Wang, C., Sun, Z., Liang, H.-Q., Xu, X., & Wei, J. (2022) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2022.105982 · Cited by 15
Personalised Therapies for Metastatic Triple-Negative Breast Cancer: When Target Is Not Everything
Capici, S., Ammoni, L. C., Meli, N., Cogliati, V., Pepe, F. F., Piazza, F., & Cazzaniga, M. E. (2022) · Cancers · doi:10.3390/cancers14153729 · Cited by 15
“TROP-2 78% sacituzumab govitecan IMMU-132-01 (phase I–II) (sacituzumab govitecan in single arm) [82] ORR: 33.”
BackgroundThe nuclear receptor TLX (NR2E1) inhibits growth and progression of triple- negative breast cancer
Nelczyk, A. T., Ma, L., Gupta, A. D., Gamage, H. E. V., McHenry, M. T., Henn, M. A., Kadiri, M., Wang, Y., Krawczyńska, N., Bendre, S. V., et al. (2022) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2022.166515 · Cited by 18
Precision Medicine and Distributive Justice: Wicked Problems for Democratic Deliberation
Fleck, L. M. (2022) · doi:10.1093/oso/9780197647721.001.0001 · Cited by 17
Ho, E. C. H., Qiu, R., Miller, E., Bilotta, M. T., FitzGerald, D., & Antignani, A. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.114047 · Cited by 17
Chartier, S., Brochard, C., Martinat, C., Coussy, F., Féron, J.-G., Kirova, Y., Cottu, P. H., Marchiò, C., & Vincent‐Salomon, A. (2022) · Histopathology · doi:10.1111/his.14852 · Cited by 16
Advances in Targeted Therapy for Non-Small-Cell Lung Cancer: Current Progress and Future Directions
Peshin, S., Takrori, E., Yazji, J. H., Haque, J., Dharia, A. A., Mithani, M. S., Anum, F., Asfeen, U. Z., Couch, J. K., Donovan, M., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262311517 · Cited by 17
“SG received FDA approval for metastatic triple-negative breast cancer following results from the IMMU-132-01 trial, which demonstrated an ORR of 33.3% and a median DOR of 7.7 months [247].”
InfluentialNanobody-Based Drug Delivery: Emerging Strategies for Targeted Cancer Therapy
Ghosh, N., Sepay, N., Paul, M., & Im, J. (2026) · International Journal of Nanomedicine · doi:10.2147/ijn.s584604 · Cited by 14
Clinicopathologic significance of TROP2 and phospho‑TROP2 in gastric cancer
Kushiyama, S., Yashiro, M., Yamamoto, Y., Sera, T., Sugimoto, A., Nishimura, S., Togano, S., Kuroda, K., Yoshii, M., Tamura, T., et al. (2021) · Molecular and Clinical Oncology · doi:10.3892/mco.2021.2267 · Cited by 16
Yuan, Y., Yost, S. E., Cui, Y., Ruel, C., Murga, M., Tang, A., Martínez, N., Schmolze, D. D., Waisman, J. R., Patel, N. H., et al. (2023) · The Oncologist · doi:10.1093/oncolo/oyad026 · Cited by 16
“Median (range) of cycles completed was 4 (2-15), including 4 (2-7) for Arm A, 4 (2-15) for Arm B, and 6 (2-10) for Arm C.”
BackgroundPrasad, K., Saggam, A., Guruprasad, K. P., Tillu, G. S., Patwardhan, B., & Satyamoorthy, K. (2024) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2024.118261 · Cited by 15
Han, X., Gao, Y., Jiang, M. P., Li, Z., Guo, J., Li, Y., Yi, J., Hou, L., Cheng, J. Q., Feng, L., et al. (2024) · Journal of Cancer · doi:10.7150/jca.95269 · Cited by 17
“While TACSTD2 has shown therapeutic progress in breast cancer [34, 35], our single-cell transcriptome analysis revealed its limited feasibility for treating ovarian cancer.”
BackgroundTackling metastatic triple-negative breast cancer with sacituzumab govitecan
Schreiber, A., Andress, M., & Diamond, J. R. (2021) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2021.1993065 · Cited by 15
“(IMMU-132-01; NCT01631552) evaluated heavily pretreated mTNBC patients who received 10 mg/kg of sacituzumab govitecan on days 1 and 8 of a 21-day cycle [33].”
BackgroundSelf-citationESMO 2020: highlights in breast cancer
Bartsch, R. (2021) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-021-00713-5 · Cited by 14
Targeting DNA repair in breast cancer
Paluch–Shimon, S., & Evron, E. (2019) · The Breast · doi:10.1016/j.breast.2019.06.007 · Cited by 15
Park, Y. H., Bianchini, G., Cortés, J., Licata, L., Vidal, M. J., Iihara, H., Roeland, E. J., Jordan, K., Scotté, F., Schwartzberg, L. S., et al. (2025) · Future Oncology · doi:10.1080/14796694.2025.2479417 · Cited by 17
“…have investigated prophylactic antie-metics for patients receiving SG. Antiemetic treatment was allowed in the IMMU-132-01 trial, and 92% of patients received antiemetic premedication; however, no specific regimen was prescribed, making it difficult to assess the impact of these regimens [36].”
Self-citation“Triple-Negative Breast Cancer Central Nervous System Metastases From the Laboratory to the Clinic”
Zimmer, A. S. (2021) · The Cancer Journal · doi:10.1097/ppo.0000000000000503 · Cited by 18
“8 months), with main adverse events being hematologic toxicity related.(74) Based on these results, the ADC has been approved for use in metastatic TNBC patients”
BackgroundMertens, R. B., Makhoul, E. P., Li, X., & Dadmanesh, F. (2023) · Annals of Diagnostic Pathology · doi:10.1016/j.anndiagpath.2023.152226 · Cited by 16
Sacituzumab Govitecan in Triple Negative Breast Cancer: A Systematic Review of Clinical Trials
Pérez-Bermejo, M., Caballero-Pascual, M., Legidos‐Garcia, M. E., Martínez-Peris, M., Mohedo, J. C., Llorca-Colomer, F., Ventura, I., Tomás‐Aguirre, F., Asins-Cubells, A., & Murillo-Llorente, M. T. (2024) · Cancers · doi:10.3390/cancers16213622 · Cited by 14
“In addition, the median response time was 2 months (95% CI 1.6–13.5) [36,37].”
BackgroundMethodResultInfluentialSchuster, E. J., Dashzeveg, N. K., Tong, F., Jia, Y., El-Shennawy, L., Zhang, T., Hoffman, A. D., Kitata, R. B., Kibria, G., Zhang, Y., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-62862-z · Cited by 17
“Future therapeutics aimed at blocking PLXNB2 and SEMA4C/4A interactions canpotentiallyserve as targetingstrategiesinbreastcancer,especiallyTNBCandcomplement existing treatments, such as pembrolizumab 69 – 71 , Sacituzumab 72,73 , and Palbociclib 74 for improved outcomes.”
Nayeem, N., Yeasmin, A., Cobos, S. N., Younes, A., Hubbard, K., & Contel, M. (2021) · ChemMedChem · doi:10.1002/cmdc.202100325 · Cited by 13
Microgravity: New aspect for breast cancer treatment, a review
Medha, M., & Roy, A. (2021) · Acta Astronautica · doi:10.1016/j.actaastro.2021.09.045 · Cited by 14
Molecular Biology Mechanisms and Emerging Therapeutics of Triple-Negative Breast Cancer
Zhang, Z., Zhang, R., & Li, D. (2023) · Biologics · doi:10.2147/btt.s426392 · Cited by 29
“This led to the approval of the new ADC for refractory metastatic TNBC.(128) Another novel HER2-targeted ADC, trastuzumab deruxtecan (T-DXd), was designed to deliver topoisomerase I inhibitor to HER2-expressing cancer cells.”
BackgroundXie, N., Xu, Y. X., Zhong, Y., Li, J., Yao, H., & Qin, T. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.617593 · Cited by 13
“Advances in targeted therapies for TNBC, include poly-ADP-ribosyl polymerase (PARP) inhibitors (19, 20), phosphoinositide 3kinase (PI3K) pathway inhibitors (21), immune checkpoint (PD−1 and PD−L1) inhibitors (22), cyclin-dependent kinase (CDK) inhibitors (23), and a promising Trop-2 targeted antibody drug conjugate (2…”
BackgroundSacituzumab Govitecan-hziy in Triple-Negative Breast Cancer
Ozaki, Y., Masuda, J., & Takano, T. (2019) · New England Journal of Medicine · doi:10.1056/nejmc1903943 · Cited by 13
Cao, Y., Wu, Z., You, Q., Xia, Y., Zhao, Q., Lousa, C. D. M., & Zhao, K. (2025) · Interdisciplinary medicine · doi:10.1002/inmd.20250038 · Cited by 14
Datopotamab deruxtecan: rational strategies, novel advancements, challenges, and future perspectives
Lauro, V. D., Rizzo, A., Tafuro, M., Fina, E., Martinelli, C., Calderaio, C., Rienzo, R. D., Pirolo, M., Fanizzi, A., Massafra, R., et al. (2025) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2025.103023 · Cited by 17
TROP2/claudin program mediates immune exclusion to impede checkpoint blockade in breast cancer
Wu, B., Thant, W., Bitman, E., Liu, T., Liu, J., Paschalis, E. I., Patel, B. K., Nawrocki, C., Xu, K. H., Nieman, L. T., et al. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-012265 · Cited by 14
Self-citationCherifi, F., Silva, A. D., Martins-Branco, D. A., Awada, A. H., & Marta, G. N. (2024) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2024.2302460 · Cited by 13
“T-DXd and SG were initially developed for the treatment of HER2-positive [9] and triple-negative ABC [10,11].”
Posani, S. H., Gillis, N. E., & Lange, C. A. (2024) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2024.106575 · Cited by 13
Nie, H., Li, B., Sun, J., Yuan, Y., Zhang, Z., Hu, H., Wang, W., Chen, Z., Wang, S., Huang, W., et al. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2024.107876 · Cited by 12
The integration of radiotherapy with systemic therapy in advanced triple-negative breast cancer
Yang, F. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104546 · Cited by 13
Khan, S. A., Jandrajupalli, S. B., Bushara, N. Z. A., Raja, R. D. P., Sharma, K., Verma, R., Raj, S., Kumar, A., & Lohani, M. (2024) · Cells · doi:10.3390/cells13242126 · Cited by 15
Update Breast Cancer 2020 Part 3 – Early Breast Cancer
Huober, J., Schneeweiß, A., Hartkopf, A. D., Müller, V., Lux, M. P., Janni, W., Ettl, J., Belleville, E., Thill, M., Fasching, P. A., et al. (2020) · Geburtshilfe und Frauenheilkunde · doi:10.1055/a-1270-7208 · Cited by 12
“The ADC sacituzumab govitecan, which has shown clear efficacy in metastatic TNBC [70], is currently being integrated in a larger study of HER2-negative patients in the post-neoadjuvant setting (SASCIA study [71]).”
BackgroundInfluentialAzzi, G., Krinshpun, S., Tin, A. S., Maninder, M., Malashevich, A. K., Malhotra, M., Vega, R. R., Billings, P. R., Rodriguez, A. A., & Aleshin, A. A. (2022) · Case Reports in Oncology · doi:10.1159/000524324 · Cited by 13
Predictive biomarkers for molecularly targeted therapies and immunotherapies in breast cancer
Kwon, M. J. (2022) · Archives of Pharmacal Research · doi:10.1007/s12272-022-01402-5 · Cited by 17
Menezes, B., Khera, E., Calopiz, M. C., Smith, M. D., Ganno, M. L., Cilliers, C., Abu‐Yousif, A. O., Linderman, J. J., & Thurber, G. M. (2022) · The AAPS Journal · doi:10.1208/s12248-022-00756-4 · Cited by 12
“6 mg/kg for Kadcyla® (microtubule inhibitor payload (26)) or 10 mg/kg for Trodelvy® (topoisomerase inhibitor (27)).”
McNamee, N., Liu, J., Poulos, R. C., Aref, A. T., & Reddel, R. R. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-3103 · Cited by 13
“Accordingly, the full publication of 108 patients did not report TROP2 assessments (37).”
Sözen, S., & Emir, S. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.104150 · Cited by 11
Santamaria, F., Roberto, M., Buccilli, D., Civita, M. A. D., Giancontieri, P., Maltese, G., Nicolella, F., Torchia, A., Scagnoli, S., Pisegna, S., et al. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104405 · Cited by 13
Targeted Treatment of Metastatic Triple‐Negative Breast Cancer: A Systematic Review
Madsen, A. M. H., Eefsen, R. L., Nielsen, D. L., & Kümler, I. (2024) · The Breast Journal · doi:10.1155/2024/9083055 · Cited by 17
Schäffler, H., Jakob, D., Huesmann, S. T., Pfister, K., Veselinovic, K., Schochter, F., Leinert, E., Fink, V., Rack, B. K., Englisch, A., et al. (2024) · Geburtshilfe und Frauenheilkunde · doi:10.1055/a-2375-5194 · Cited by 11
Astore, S., Oneda, E., & Zaniboni, A. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104535 · Cited by 13
Emerging Therapies for Brain Metastases in NSCLC, Breast Cancer, and Melanoma: A Critical Review
Podder, V., Ranjan, T., Gowda, M., Camacho, A. M., & Ahluwalia, M. S. (2024) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-024-01388-1 · Cited by 14
“Around 50% of advanced TNBC patients develop BMs, with a median OS of only 7.3 months [75, 76].”
InfluentialAn, J., Li, G., Zhang, Y., Feng, M., Kong, W., Jiang, H., Luo, S., Li, W., Xu, C., Han, L., et al. (2025) · Gynecologic Oncology · doi:10.1016/j.ygyno.2025.09.001 · Cited by 19
Clinical perspective on management of key adverse events with sacituzumab govitecan
Tolaney, S. M., Sonpavde, G., Tarantino, P., Lustberg, M. B., & Rugo, H. S. (2025) · The Oncologist · doi:10.1093/oncolo/oyaf311 · Cited by 14
Self-citationAmin, S., Tolaney, S. M., Cambron‐Mellott, M. J., Beusterien, K. M., Maculaitis, M. C., Mulvihill, E., Shinde, R., & McLaurin, K. K. (2022) · Future Oncology · doi:10.2217/fon-2021-0761 · Cited by 13
Self-citationAdvancing antibody-drug conjugates in gynecological malignancies: myth or reality?
Nerone, M., Grande, M. D., Sessa, C., & Colombo, I. (2022) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2022.00077 · Cited by 11
“Four ADCs are available in clinical practice for the treatment of patients with solid tumors: T-DM1 and trastuzumab deruxtecan (T-DXd) for human epidermal growth factor 2 (HER2)-positive breast cancer [8], sacituzumab govitecan for triple-negative breast cancer [9], and enfortumab vedotin for metastatic urothelial car…”
BackgroundMethodTreatment Progress in Triple Negative Breast Cancer
(2022) · European Journal of Gynaecological Oncology · doi:10.31083/j.ejgo4302040 · Cited by 11
Loeser, A. L., Gao, L., Bardia, A., Burkard, M. E., Kalinsky, K. M., Peppercorn, J. M., Rugo, H. S., Carlson, M., Cowden, J., Glenn, L. K., et al. (2022) · Breast Cancer Research and Treatment · doi:10.1007/s10549-022-06755-5 · Cited by 12
Self-citationAntibody-Drug Conjugates in Breast Cancer: What Is Beyond HER2?
Nicolò, E., Repetto, M., Bielo, L. B., Tarantino, P., & Curigliano, G. (2022) · The Cancer Journal · doi:10.1097/ppo.0000000000000629 · Cited by 11
“5 months, and median overall survival (mOS) was 13 months.(11) These results led to accelerated approval of SG by the Food and Drug Administration, with subsequent full approval in April 2021 for patients with metastatic TNBC (mTNBC) who have received at least 2 prior systemic therapies (≥1 in metastatic setting), bas…”
BackgroundA colorimetric biosensor to track Trop-2 status of tumor cells for diagnosis of breast cancer
Zeng, T., Wu, S., Liang, Q., Shi, H., Gong, J., Duan, N., Li, W., Li, G., & Yin, Y. (2023) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2023.134020 · Cited by 11
Current and Emerging Treatments for Urothelial Carcinoma: A Focus on Enfortumab Vedotin
Shafique, M. A., Haseeb, A., Siddiq, M. A., Mussarat, A., Rangwala, H. S., & Mustafa, M. S. (2023) · Cancer Management and Research · doi:10.2147/cmar.s418009 · Cited by 13
“By binding to Trop-2, it releases the chemotherapy drug SN-38 inside the cancer cells, leading to cell death and inhibiting tumor growth.(22) Initially approved for metastatic triple-negative breast cancer (mTNBC) in patients who have undergone prior therapies,(23) it has shown promising results with an objective resp…”
BackgroundZhao, M., Sun, B., Wang, Y., Qu, G., Yang, H., & Wang, P. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.694491 · Cited by 11
“However, recent studies have shown that TNBC is heterogeneous and has multiple pathological subtypes (45).”
BackgroundSABR in oligometastatic breast cancer: Current status and future directions
Stewart, R., White, M. A., Tan, J., Siva, S., Karroum, L., & David, S. (2021) · The Breast · doi:10.1016/j.breast.2021.10.009 · Cited by 11
“Other new therapies include Sacituzumab, an antibody-drug conjugate, which has activity in previously treated TNBC including improvements in PFS and overall survival when compared with physician's choice chemotherapy [21].”
BackgroundAtiq, S. O., Hirshman, N. A., Shariff, A. I., & Zhang, T. (2021) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2021.10.002 · Cited by 11
Nayeem, N., Sauma, S., Ahad, A., Rameau, R. D., Kebadze, S., Bazett, M., Park, B., Casaccia, P., Prabha, S., Hubbard, K., et al. (2024) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.4c00020 · Cited by 12
Manna, M., Brabant, M., Greene, R., Chamberlain, M. D., Kumar, A., Alimohamed, N. S., & Brezden‐Masley, C. (2024) · Current Oncology · doi:10.3390/curroncol31090422 · Cited by 12
“The hydrolysable linker is designed to liberate cytotoxic SN-38 in the acidic tumor microenvironment without prerequisite internalization and subsequent enzymatic cleavage [21], enabling “bystander effect” tumor cell killing [22], as free SN-38 is membrane-permeable [20].”
BackgroundJacot, W., Chateau, M., Thézenas, S., Guiu, S., Firmin, N., Lafont, V., Lazennec, G., Theillet, C. G., & Boissière‐Michot, F. (2025) · Cancer Medicine · doi:10.1002/cam4.70615 · Cited by 11
“Sacituzumab govitecan, a Trop- 2-directed monoclonal antibody coupled to a topoisomerase 1 inhibitor payload, has since been approved and is currently used in clinical practice in heavily pretreated patients with metastatic TNBC [10, 11].”
Extracellular Domain Shedding of TROP2 Activates EGFR Signaling to Drive Prostate Cancer Metastasis
Liu, S., Hsu, E., Aslan, M., Garcia-Marques, F. J., Shen, M., Hartono, A. B., Solano, F., Le, K., Hwang, H., Lee, C. S., et al. (2025) · Cancer Research · doi:10.1158/0008-5472.can-24-4855 · Cited by 10
Novel targeted therapies and immunological strategies for breast cancer treatment
Mussa, A., Hamid, M. A. M., Talib, M., Ehinnou, I. B., Bragoli, A. J., Hajissa, K., Mokhtar, N. F., Mohamud, R., Al-Hatamleh, M. A. I., & Hassan, R. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.117929 · Cited by 10
Mishra, A., Abelman, R. O., Cunneely, Q. E., Putaturo, V. R., Deshpande, A., Bell, R., Seider, E. M., Xu, K. H., Shan, M., Kelly, J., et al. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2601563123 · Cited by 10
Self-citationAdvances with antibody-drug conjugates in breast cancer treatment
Subhan, M. A., & Torchilin, V. P. (2021) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2021.10.016 · Cited by 10
Baek, G., Jung, L., Duong, A., & Gralow, J. R. (2021) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552211057486 · Cited by 10
“SG is an antibody–drug conjugate (ADC) that received FDA approval based on phase I/II data demonstrating improvement in progression-free survival (PFS) and overall survival (OS).(1) Results from the recently published randomized phase III ASCENT trial of SG in mTNBC confirm the findings from earlier phase data, indica…”
BackgroundMethodResultInfluentialManagement of triple-negative breast cancer in the era of novel therapies: A narrative review
Sharma, R., & Gogia, A. (2021) · Cancer Research Statistics and Treatment · doi:10.4103/crst.crst_226_21 · Cited by 10
Prognostic/predictive markers in systemic therapy resistance and metastasis in breast cancer
Hobbs, E. A., Chen, N., Kuriakose, A., Bonefas, E., & Lim, B. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221112698 · Cited by 10
Molecular imaging of pancreatic ductal adenocarcinoma
Huang, W., Huang, G., An, S., & Liu, J. (2023) · View · doi:10.1002/viw.20230029 · Cited by 10
Vlachou, E., Johnson, B. A., & Hoffman-Censits, J. H. (2024) · Clinical Medicine Insights Oncology · doi:10.1177/11795549241290787 · Cited by 12
Yang, P., Zhang, H., Li, J., Li, Z., Liu, Z., Wang, M., Zhao, F., Zhao, J., Shen, G., & Zhao, Y. D. (2024) · Therapeutic Advances in Drug Safety · doi:10.1177/20420986241304680 · Cited by 12
Lee, C., Ryu, H. W., Kim, S., Kim, M., Oh, S., Ahn, K., & Park, J. (2020) · Scientific Reports · doi:10.1038/s41598-020-77401-7 · Cited by 10
The Expanding Role of Chemistry in Optimizing Proteins for Human Health Applications
Roman, B. I. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00294 · Cited by 10
Qiu, Y., Chen, Y., Shen, H., Yan, S., Li, J., & Wu, W. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1388869 · Cited by 11
Metadata
- Authors
- Bardia, A., Mayer, I. A., Vahdat, L. T., Tolaney, S. M., Isakoff, S. J., Diamond, J. R., O’Shaughnessy, J., Moroose, R. L., Santin, A. D., Abramson, V. G., Shah, N. C., Rugo, H. S., Goldenberg, D. M., Sweidan, A. M., Iannone, R., Washkowitz, S., Sharkey, R. M., Wegener, W. A., & Kalinsky, K.
- Affiliations
- Harvard University (US)
- Vanderbilt University (US)
- Cornell University (US)
- Orlando Health (US)
- University of California, San Francisco (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-02-21
- Volume
- 380
- Issue
- 8
- Pages
- 741-751
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2917403028
- Cited by
- 874
- References
- 37
- Citations by year
- 2026: 76 · 2025: 103 · 2024: 111 · 2023: 125 · 2022: 167 · 2021: 167 · 2020: 91 · 2019: 32
- FWCI
- 36.24
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Immunomedics Inc
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
- Keywords
- sacituzumab govitecan, antibody-drug conjugates, metastatic triple-negative breast cancer, TROP2, SN-38, refractory disease, objective response rate, duration of response, progression-free survival, overall survival, safety, febrile neutropenia, anemia, neutropenia
- MeSH terms
- Irinotecan, Progression-Free Survival, Adult, Aged, Aged, 80 and over, Anemia, Antigens, Neoplasm, Antineoplastic Agents, Camptothecin, Diarrhea, Dose-Response Relationship, Drug, Female, Humans, Infusions, Intravenous, Male, Middle Aged, Neutropenia, Cell Adhesion Molecules, Survival Rate, Immunoconjugates, Antibodies, Monoclonal, Humanized, Triple Negative Breast Neoplasms
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.